Combining CPI-613 (as known as Devimistat which is a potent inhibitor for TCA enzymes) with CHC can inhibit pancreatic carcinoma cell proliferation and induce apoptosis [96], suggesting the potential for combined use of MCT1 inhibitor and other anticancer drugs for cancer therapy. Here, SLC16A1 is linked to cancer.